Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NN-6177
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
NN-6177 is a synthetic peptide drug developed by Novo Nordisk. It acts as a dual agonist (co-agonist) of the glucagon receptor (GCGR) and the glucagon-like peptide 1 receptor (GLP‑1R). This mechanism aims to combine the metabolic benefits of both pathways, potentially improving outcomes in metabolic diseases such as nonalcoholic steatohepatitis (NASH). The drug is currently in Phase 1 clinical development for NASH. As a co‑agonist, it modulates both GCGR and GLP‑1R activity, which may result in improved liver health, weight loss, and glycemic control[1][2][6].
- Other names
- glucagon/GLP-1 co-agonist (Novo Nordisk)GG-co-agonist
02
Targets
GLP1R (GLP-1R)GCGR (Glucagon receptor)
Beyond the preview
Go deeper on NN-6177.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NN-6177.